filmov
tv
LEADER: Lliraglutide and cardiovascular outcomes in type 2 diabetes ( and use in obesity)
Показать описание
En este vídeo os informo acerca del Liraglutide, un fármaco que se administra por vía subcutánea y ayuda a controlar la dieabetes y a perder peso en pacientes con obesidad y sobrepeso, que además tiene un efecto protector cardiovascular y reduce la tensión ligeramente.
LEADER: Lliraglutide and cardiovascular outcomes in type 2 diabetes ( and use in obesity)
Medicine Grand Rounds: Diabetes and Cardiovascular Disease 3/26/19
Cardiovascular disease treatment, Liraglutide, and modifying diabetes risk factors
Understanding Cardiovascular Benefit With the LEADER Trial
5' Trials - LEADER (Liraglutide)
AHA 2015 | Liraglutide for High-Risk Heart Failure Patients
GLP-1 Agonists in T2D: Cardiovascular Outcomes Data
Cardiovascular Outcomes With GLP-1 Receptor Agonists in Type 2 Diabetes
Karol Watson, MD, and Steven Nissen, MD: Liraglutide on Cardiovascular Risk
Keynote Presentation: Heart Failure with Reduced Ejection Fraction (G. MICHAEL FELKER, MD)
GLP-1 ( Liraglutide )&Cardiovascular Disease in Patients with Type 2 Diabetes,Organized by ICC, ...
Understanding Cardiovascular Outcomes Trials
EASD 2019 Lawrence Leiter
Steven Nissen, MD, on Liraglutide
State of the Art: Diabetes Management with Respect to CVD and CKD in 2018
Cardiovascular Outcomes with Antidiabetic Agents
Journal Club- June 2018: Semaglutide and CV Outcomes
Examining Cardiovascular Outcomes Trials
Poster #754 - 360° 4K EASD 2018
Cardiovascular Disease Burden in Type 2 Diabetes: Strategies to Improve Outcomes
Darren McGuire | Cardiovascular effects of diabetes medications: Lessons learned from CVOTs
Researcher comment: The PIONEER 6 oral semaglutide cardiovascular outcomes study | Mansoor Husain
Prof Melanie Davies - 'Do GLP-1 analogues and SGLT2 inhibitors have a role beyond type 2 diabet...
DRF 19: Cardiovascular Outcomes for Diabetes Drugs: Lessons Learned and Path Forward
Комментарии